China Innovative Drug Stocks Open Higher; Haizheng Pharma Hits Limit-Up

The move looks like a single-name limit-up setting the tone for the whole innovative-drug complex rather than a broad, independently confirmed rally — the gainers listed are a tight cluster of small and mid-cap names moving together at the open, which is a momentum signature more than a fundamental one. What matters is whether this is a one-session burst or the start of sustained interest in the sector, and whether Haizheng's limit-up holds through the close. Watch for follow-through breadth beyond the named movers; a narrow open like this often fades without it.